Company registration number:
05657101
Medipharma UK Limited
Unaudited filleted financial statements
31 March 2024
Medipharma UK Limited
Contents
Statement of financial position
Notes to the financial statements
Medipharma UK Limited
Statement of financial position
31 March 2024
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
Note |
£ |
|
£ |
|
£ |
|
£ |
|
|
|
|
|
|
|
|
|
|
Fixed assets |
|
|
|
|
|
|
|
|
|
Intangible assets |
|
5 |
625,900 |
|
|
|
682,800 |
|
|
Tangible assets |
|
6 |
733,053 |
|
|
|
724,212 |
|
|
|
|
|
__________ |
|
|
|
__________ |
|
|
|
|
|
|
|
1,358,953 |
|
|
|
1,407,012 |
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Stocks |
|
|
189,830 |
|
|
|
185,220 |
|
|
Debtors |
|
|
928,807 |
|
|
|
931,979 |
|
|
Cash at bank and in hand |
|
|
1,610,737 |
|
|
|
1,400,062 |
|
|
|
|
|
__________ |
|
|
|
__________ |
|
|
|
|
|
2,729,374 |
|
|
|
2,517,261 |
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
within one year |
|
|
(
781,181) |
|
|
|
(
732,514) |
|
|
|
|
|
__________ |
|
|
|
__________ |
|
|
Net current assets |
|
|
|
|
1,948,193 |
|
|
|
1,784,747 |
|
|
|
|
|
__________ |
|
|
|
__________ |
Total assets less current liabilities |
|
|
|
|
3,307,146 |
|
|
|
3,191,759 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
__________ |
|
|
|
__________ |
Net assets |
|
|
|
|
3,307,146 |
|
|
|
3,191,759 |
|
|
|
|
|
__________ |
|
|
|
__________ |
|
|
|
|
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
|
|
|
|
|
Called up share capital |
|
|
|
|
1,000 |
|
|
|
1,000 |
Profit and loss account |
|
|
|
|
3,306,146 |
|
|
|
3,190,759 |
|
|
|
|
|
__________ |
|
|
|
__________ |
Shareholders funds |
|
|
|
|
3,307,146 |
|
|
|
3,191,759 |
|
|
|
|
|
__________ |
|
|
|
__________ |
|
|
|
|
|
|
|
|
|
|
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
-
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
-
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the
board of directors
and authorised for issue on
10 May 2024
, and are signed on behalf of the board by:
Mr Balbir Singh Chahal
Director
Company registration number:
05657101
Medipharma UK Limited
Notes to the financial statements
Year ended 31 March 2024
1.
General information
The company is a private company limited by shares, registered in England. The address of the registered office is 29 Oak Tree Lane, Selly Oak, Birmingham, B29 6JE.
2.
Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Goodwill
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
|
|
|
|
Goodwill |
- |
5% % |
straight line |
|
|
|
|
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.
Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
|
|
|
|
|
|
Fittings fixtures and equipment |
- |
10% % |
straight line |
|
Motor vehicles |
- |
25% % |
straight line |
|
|
|
|
|
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.
4.
Employee numbers
The average number of persons employed by the company during the year amounted to
23
(2023:
22
).
5.
Intangible assets
|
|
Goodwill |
Total |
|
|
|
|
|
|
£ |
£ |
|
|
|
|
|
Cost |
|
|
|
|
|
|
|
At 1 April 2023 and 31 March 2024 |
1,138,000 |
1,138,000 |
|
|
|
|
|
|
__________ |
__________ |
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
At 1 April 2023 |
455,200 |
455,200 |
|
|
|
|
|
Charge for the year |
56,900 |
56,900 |
|
|
|
|
|
|
__________ |
__________ |
|
|
|
|
|
At 31 March 2024 |
512,100 |
512,100 |
|
|
|
|
|
|
__________ |
__________ |
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
At 31 March 2024 |
625,900 |
625,900 |
|
|
|
|
|
|
__________ |
__________ |
|
|
|
|
|
At 31 March 2023 |
682,800 |
682,800 |
|
|
|
|
|
|
__________ |
__________ |
|
|
|
|
|
|
|
|
|
|
|
|
6.
Tangible assets
|
|
Freehold property |
Fixtures, fittings and equipment |
Motor vehicles |
Total |
|
|
|
|
|
£ |
£ |
£ |
£ |
|
|
|
|
Cost |
|
|
|
|
|
|
|
|
At 1 April 2023 and 31 March 2024 |
720,775 |
177,537 |
4,241 |
902,553 |
|
|
|
|
|
__________ |
__________ |
__________ |
__________ |
|
|
|
|
Depreciation |
|
|
|
|
|
|
|
|
At 1 April 2023 |
- |
174,100 |
4,241 |
178,341 |
|
|
|
|
Charge for the year |
- |
(
8,841) |
- |
(
8,841) |
|
|
|
|
|
__________ |
__________ |
__________ |
__________ |
|
|
|
|
At 31 March 2024 |
- |
165,259 |
4,241 |
169,500 |
|
|
|
|
|
__________ |
__________ |
__________ |
__________ |
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
|
At 31 March 2024 |
720,775 |
12,278 |
- |
733,053 |
|
|
|
|
|
__________ |
__________ |
__________ |
__________ |
|
|
|
|
At 31 March 2023 |
720,775 |
3,437 |
- |
724,212 |
|
|
|
|
|
__________ |
__________ |
__________ |
__________ |
|
|
|
|
|
|
|
|
|
|
|
|
7.
Controlling party
The company was controlled throughout the period by its director Mr B S Chahal by virtue of the fact that he holds 75% of the company's ordinary share capital.